Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Video-interview with Dr. Alok Khorana who presents the latest results of the CASSINI trial regarding
rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy
2. Subgroup and sensitivity analyses of ECHELON-1 evaluating brentuximab vedotin + AVD vs. ABVD in the
frontline management of advanced classical Hodgkin lymphoma
3. Superior clinical outcomes with ibrutinib-obinutuzumab compared to chlorambucil-obinutuzumab in the
first-line treatment of chronic lymphocytic leukemia
4. First prospective evidence supporting iron chelation in patients with low and intermediate-1 risk
myelodysplastic syndromes
5. Four cycles of R-CHOP is as effective as six cycles in young patients with favorable-risk diffuse
large B-cell lymphoma